Skip to main content
Top
Literature
1.
go back to reference Kamiya M, Sato N, Matsuda J, Nozaki A, Akiya M, Sato T, Okazaki H, Takahashi Y, Shimizu W (2020) Predictors of responders for low-dose carperitide monotherapy in patients with acute heart failure. Heart Vessels 35:59–68CrossRefPubMed Kamiya M, Sato N, Matsuda J, Nozaki A, Akiya M, Sato T, Okazaki H, Takahashi Y, Shimizu W (2020) Predictors of responders for low-dose carperitide monotherapy in patients with acute heart failure. Heart Vessels 35:59–68CrossRefPubMed
2.
go back to reference Kajimoto K, Sashida Y, Minami Y, Yumino D, Kawarai H, Kasanuki H (2009) Systolic blood pressure at admission as a predictor of the response to initial carperitide therapy in patients hospitalized for acute decompensated heart failure with left ventricular systolic dysfunction. Cardiovasc Drugs Ther 23:481–488CrossRefPubMed Kajimoto K, Sashida Y, Minami Y, Yumino D, Kawarai H, Kasanuki H (2009) Systolic blood pressure at admission as a predictor of the response to initial carperitide therapy in patients hospitalized for acute decompensated heart failure with left ventricular systolic dysfunction. Cardiovasc Drugs Ther 23:481–488CrossRefPubMed
3.
go back to reference Felker GM, O'Connor CM, Braunwald E (2009) Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2:56–62CrossRefPubMedPubMedCentral Felker GM, O'Connor CM, Braunwald E (2009) Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2:56–62CrossRefPubMedPubMedCentral
4.
go back to reference Triposkiadis FK, Butler J, Karayannis G, Starling RC, Filippatos G, Wolski K, Parissis J, Parisis C, Rovithis D, Koutrakis K, Skoularigis J, Antoniou CK, Chrysohoou C, Pitsavos C, Stefanadis C, Nastas J, Tsaknakis T, Mantziari L, Giannakoulas G, Karvounis H, Kalogeropoulos AP, Giamouzis G (2014) Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the dopamine in acute decompensated heart failure II (DAD-HF II) trial. Int J Cardiol 172:115–121CrossRefPubMed Triposkiadis FK, Butler J, Karayannis G, Starling RC, Filippatos G, Wolski K, Parissis J, Parisis C, Rovithis D, Koutrakis K, Skoularigis J, Antoniou CK, Chrysohoou C, Pitsavos C, Stefanadis C, Nastas J, Tsaknakis T, Mantziari L, Giannakoulas G, Karvounis H, Kalogeropoulos AP, Giamouzis G (2014) Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the dopamine in acute decompensated heart failure II (DAD-HF II) trial. Int J Cardiol 172:115–121CrossRefPubMed
5.
go back to reference Voors AA, Davison BA, Felker GM, Ponikowski P, Unemori E, Cotter G, Teerlink JR, Greenberg BH, Filippatos G, Teichman SL, Metra M (2011) Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. Eur J Heart Fail 13:961–967CrossRefPubMed Voors AA, Davison BA, Felker GM, Ponikowski P, Unemori E, Cotter G, Teerlink JR, Greenberg BH, Filippatos G, Teichman SL, Metra M (2011) Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. Eur J Heart Fail 13:961–967CrossRefPubMed
6.
go back to reference Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Abe Y, Saito T, Ohwada T, Suzuki H, Saitoh S, Kubota I, Takeishi Y (2013) Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol 53:1277–1285CrossRefPubMedPubMedCentral Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Abe Y, Saito T, Ohwada T, Suzuki H, Saitoh S, Kubota I, Takeishi Y (2013) Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol 53:1277–1285CrossRefPubMedPubMedCentral
7.
go back to reference Kinugawa K, Sato N, Inomata T (2018) Effects of tolvaptan on volume overload in patients with heart failure. Int Heart J 59:1368–1377CrossRefPubMed Kinugawa K, Sato N, Inomata T (2018) Effects of tolvaptan on volume overload in patients with heart failure. Int Heart J 59:1368–1377CrossRefPubMed
8.
go back to reference Morrow DA, Velazquez EJ, DeVore AD, Prescott MF, Duffy CI, Gurmu Y, McCague K, Rocha R, Braunwald E (2019) Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Eur Heart J 40:3345–3352CrossRefPubMedPubMedCentral Morrow DA, Velazquez EJ, DeVore AD, Prescott MF, Duffy CI, Gurmu Y, McCague K, Rocha R, Braunwald E (2019) Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Eur Heart J 40:3345–3352CrossRefPubMedPubMedCentral
9.
go back to reference Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP (2010) Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375:1255–1266CrossRefPubMed Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP (2010) Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375:1255–1266CrossRefPubMed
Metadata
Title
Therapeutic strategy using low-dose carperitide in patients with acute heart failure
Authors
Masataka Kamiya
Naoki Sato
Wataru Shimizu
Publication date
01-12-2020
Publisher
Springer Japan
Published in
Heart and Vessels / Issue 12/2020
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-020-01636-7

Other articles of this Issue 12/2020

Heart and Vessels 12/2020 Go to the issue